Cybin Inc., a trailblazing clinical-stage biopharmaceutical company, is teaming up with the renowned continuing education organisation, Fluence, to enhance its EMBARK facilitator training programme.
This collaboration is in anticipation of a major global Phase 3 trial of Cybin’s drug CYB003, a unique version of psilocybin, being developed as a potential treatment for severe depression.
For those unfamiliar, psilocybin is a naturally occurring psychedelic compound found in specific mushrooms, and has shown promise in recent years for treating various mental health conditions.
The EMBARK for Clinical Trials training model, aptly named “EMBARKCT”, is tailored for individuals with prior experience in guiding psychedelic sessions.
As part of this partnership, Fluence will assist Cybin in cherry-picking and training facilitators for the upcoming trial.
They will also develop video content and offer diverse training methods to bolster and validate facilitator skills.
Cybin’s CEO, Doug Drysdale, expressed enthusiasm for the partnership, stating that Fluence’s proficiency in clinical training will help deliver top-notch, scalable training in line with the extensive Phase 3 trial.
Echoing Drysdale’s sentiments, Dr. Ingmar Gorman, co-founder of Fluence, conveyed excitement at the prospect of joining forces with Cybin. He highlighted the importance of such collaborations in the ever-evolving psychedelic therapy landscape.
A brief overview of the two companies:
Cybin Inc. is dedicated to crafting effective psychedelic-based treatments for mental health issues.
Founded in 2019 with operations spanning multiple countries, the company is making waves with its innovative drug solutions, particularly CYB003 and CYB004, focusing on severe depression and anxiety disorders, respectively.
For more about Cybin, you can visit their website at www.cybin.com.
Fluence is a frontrunner in psychedelic therapy training, offering robust, evidence-supported training to professionals eager to integrate psychedelic therapies into their work.
With this alliance, both companies are poised to make significant advances in the burgeoning field of psychedelic therapy.
